Vanguard Rabies

País: Regne Unit

Idioma: anglès

Font: VMD (Veterinary Medicines Directorate)

ingredients actius:

Rabies virus

Disponible des:

Zoetis UK Limited

Codi ATC:

QI07AA02

Designació comuna internacional (DCI):

Rabies virus

formulario farmacéutico:

Suspension for injection

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Cats, Dogs

Área terapéutica:

Inactivated Viral Vaccine

Estat d'Autorització:

Expired

Data d'autorització:

2000-05-23

Fitxa tècnica

Revised: October 2015
Minor amendment to section 6.1
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE IMMUNOLOGICAL VETERINARY PRODUCT
Vanguard Rabies
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
QUANTITY/DOSE
ACTIVE CONSTITUENTS: Rabies Virus (Strain Flury
LEP) (Inactivated, concentrated and purified rabies
virus antigen
* Based on Ph. Eur. serology test)
≥ 3.25 IU/ml of Rabies
glycoprotein inducing ≥ 1.4
log10 IU/ml*
ADJUVANT: Aluminium Hydroxide
1.7-2.1 mg
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Vanguard
Rabies
vaccine
is
a
sterile
opaque
suspension
for
subcutaneous
injection, with an off-white precipitate which readily resuspends on
shaking.
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Cats, dogs.
4.2.
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of cats and dogs to prevent infection and
mortality due
to rabies.
An
antibody
response
normally
develops
within
7-14
days
after
vaccination.
Vaccinated animals should not be exposed to the risk of rabies
infection for 14
days. The specific immune response confers immunity for up to 3 years.
4.3.
CONTRAINDICATIONS
Do not use in unhealthy animals.
Do not use in pregnant animals.
4.4.
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Revised: October 2015
Minor amendment to section 6.1
Page 2 of 5
4.5.
SPECIAL PRECAUTIONS FOR USE
i)
Special precautions for use in animals
Do
not
vaccinate
animals
for
at
least
one
month
following
the
administration of immuno-suppressive drugs.
ii)
Special
precautions
to
be
taken
by
the
person
administering
the
veterinary medicinal product to animals
No special precautions apply.
4.6.
ADVERSE REACTIONS
As with all vaccines, occasional hypersensitivity may occur. In such
cases,
appropriate treatment, such as adrenalin, should be administered
without delay.
In dogs, treatment with the vaccine produces oedematous swelling of up
to 3.8 cm
maximum diameter (5.4 cm
3
max. volume) at the site of injection. This swelling
resolves with time and disappears by 21 days after tr